SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Peter Singleton who wrote (21380)5/25/1998 4:16:00 PM
From: RXGOLF  Respond to of 32384
 
Wow Peter!!! Thanks for your time and the great post. Very reassuring to here things(and I mean lots of things)are going in the direction we hoped!

Thanks again,
Greg



To: Peter Singleton who wrote (21380)5/25/1998 4:43:00 PM
From: Peter Singleton  Read Replies (2) | Respond to of 32384
 
p.s., on the shareholder meeting thoughts, the market size numbers I mentioned for CTCL, addressable by the various LGND products (Targretin gel 8,000 patients, Ontak 16,000 patients) look more like US + Europe, not just US ...



To: Peter Singleton who wrote (21380)5/25/1998 6:17:00 PM
From: Russian Bear  Respond to of 32384
 
Peter,

Thank you very much for that thorough report. Very interesting reading.

Best regards,
RB



To: Peter Singleton who wrote (21380)5/26/1998 6:50:00 AM
From: Henry Niman  Respond to of 32384
 
Walter, Herceptin targets HER2, while DAB389-EGF targets HER1. Both receptors are related, but distinct and over expression varies from patient to patient (about 30% over express HER2 - I'm not sure how many over express HER1) and of course different normal cells have different expression profiles for the two receptors.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News